About Chimerix
Chimerix is a company based in Durham (United Kingdom) founded in 2002 was acquired by Jazz Pharmaceuticals in March 2025. Chimerix has raised $95.23 million across 5 funding rounds from investors including Jazz Pharmaceuticals, New Leaf Venture Partners and Frazier Healthcare Partners. The company has 72 employees as of December 31, 2023. Chimerix has completed 1 acquisition, including Oncoceutics. Chimerix offers products and services including TEMBEXA, ONC201, and ONC206. Chimerix operates in a competitive market with competitors including Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others.
- Headquarter Durham, United Kingdom
- Employees 72 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$30 K (USD)-100as on Dec 31, 2023
-
Net Profit
-$88.39 M (USD)-8as on Dec 31, 2024
-
EBITDA
-$96.57 M (USD)-4as on Dec 31, 2024
-
Total Equity Funding
$95.23 M (USD)
in 5 rounds
-
Latest Funding Round
$122 M (USD), Post-IPO
Nov 01, 2014
-
Investors
Jazz Pharmaceuticals
& 9 more
-
Employee Count
72
as on Dec 31, 2023
- Investments & Acquisitions
-
Acquired by
Jazz Pharmaceuticals
(Mar 05, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Chimerix
Chimerix offers a comprehensive portfolio of products and services, including TEMBEXA, ONC201, and ONC206.
Treats serious viral diseases through targeted medication.
Addresses gliomas and brain tumors via innovative therapy.
Targets central nervous system tumors for improved outcomes.
People of Chimerix
Unlock access to complete
Funding Insights of Chimerix
Chimerix has successfully raised a total of $95.23M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $122 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Chimerix
Chimerix has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Jazz Pharmaceuticals, New Leaf Venture Partners and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
VC firm focusing on life science sector
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked |
Investor details for Chimerix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chimerix
Chimerix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oncoceutics.
Investment portfolio details for Chimerix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Clinical-stage drug development company focused on oncology
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Chimerix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Chimerix
Detailed financials for Chimerix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Chimerix Comparisons
Peer comparison for Chimerix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Chimerix
Chimerix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
Detailed competitors of Chimerix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Chimerix
Complete news archive for Chimerix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chimerix
Chimerix was founded in 2002 and raised its 1st funding round 2 years after it was founded.
Chimerix is headquartered in Durham, United Kingdom.
Chimerix is a funded company, having raised a total of $95.23M across 5 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Chimerix is 72.
Annual revenue of Chimerix is $30K as on Dec 31, 2023.
The company was founded in 2002 in Durham, United Kingdom, within the biotechnology sector. Antiviral oral therapeutics are developed, with a pipeline that includes Brincidofovir for smallpox treatment, ONC201 for mutant glioma, DSTAT for acute myeloid leukemia, and ONC206 for solid tumors. Quality of life is improved for patients across transplant, oncology, acute care, and global health settings through these operations.
Chimerix's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Chimerix offers TEMBEXA, ONC201, and ONC206.
Chimerix has made 1 acquisition, including Oncoceutics.
Chimerix has 10 investors. Key investors include Jazz Pharmaceuticals, New Leaf Venture Partners, Frazier Healthcare Partners, Canaan, and Pappas Capital.